Investment Thesis
Pure Bioscience faces existential financial distress with negative stockholders' equity of -$6.3M, indicating technical insolvency and complete equity wipeout for shareholders. The company exhibits a critical liquidity crisis (0.25x current ratio), burns $889K annually in free cash flow, and maintains only $198K cash against $7.1M liabilities with stagnant revenue, leaving minimal operational runway.
Strengths
- Gross margin of 59.8% indicates underlying unit economics are viable if business could scale revenue
- No long-term debt burden simplifies restructuring obligations
- Net loss improved 28.4% YoY suggesting modest cost control initiatives underway
Risks
- Negative stockholders' equity of -$6.3M represents technical insolvency with complete equity value destruction
- Severe liquidity crisis with 0.25x current ratio and only $198K cash versus $7.1M total liabilities creates imminent payment default risk
- Negative free cash flow of -$889K and flat revenue (-0.2% YoY) indicate unsustainable burn with no growth catalyst for turnaround
- Operating margin of -92.3% demonstrates business generates massive losses relative to revenue scale
Key Metrics to Watch
- Quarterly cash burn rate and months of cash runway remaining
- Revenue stabilization and gross profit absolute dollars
- Short-term liability maturity schedule and refinancing ability
Financial Metrics
Revenue
1.2M
Net Income
-1.2M
EPS (Diluted)
$-0.01
Free Cash Flow
-889.0K
Total Assets
788.0K
Cash
198.0K
Profitability Ratios
Gross Margin
59.8%
Operating Margin
-92.3%
Net Margin
-108.6%
ROE
N/A
ROA
-158.5%
FCF Margin
-77.3%
Balance Sheet & Liquidity
Current Ratio
0.25x
Quick Ratio
0.18x
Debt/Equity
N/A
Debt/Assets
896.1%
Interest Coverage
-5.59x
Long-term Debt
0.0
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-14T18:57:22.537437 |
Data as of: 2026-01-31 |
Powered by Claude AI